With regard to the mechanisms underlying ALK fusion-induced PD-L1 in NSCLC, several studies demonstrated the involvement of PI3K and MAPK activation [47], as well as the Hippo pathway [52]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.